<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460147</url>
  </required_header>
  <id_info>
    <org_study_id>001001</org_study_id>
    <nct_id>NCT01460147</nct_id>
  </id_info>
  <brief_title>Osteoporosis and MRI Study in Hemophilia</brief_title>
  <official_title>Bone and Joint Health in an Adult Hemophilia Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate bone mineral density in adult subjects with&#xD;
      hemophilia versus a comparator population without hemophilia (non-hemophilia age- and&#xD;
      gender-matched database) by using the following diagnostic means: dual-energy X-ray&#xD;
      absorptiometry (DXA) scanning, clinical scales, quality of life (QOL) scales and biomarkers.&#xD;
      In addition to this osteoporosis study, hemophilic arthropathy of the knee with respect to&#xD;
      loss of knee cartilage will also be explored by using magnetic resonance imaging (MRI&#xD;
      substudy). No investigational product will be dispensed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 30, 2011</start_date>
  <completion_date type="Actual">April 13, 2012</completion_date>
  <primary_completion_date type="Actual">April 13, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Endpoint: Z-Score by dual-energy X-ray absorptiometry (DXA) at baseline</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinal Endpoint: Change in bone mineral density by DXA over 2 years</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinal Endpoint: Rate of loss of knee cartilage parameters over 2 years by MRI</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Bone Mineral Density</condition>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>DXA scan + MRI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DXA scan + MRI</intervention_name>
    <description>This is a non-drug study. Subjects will receive a dual-energy X-ray absorptiometry (DXA) scan (in the main osteoporosis study) and will undergo magnetic resonance imaging (in the MRI substudy).</description>
    <arm_group_label>DXA scan + MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and at least 25 years old at the time of screening&#xD;
&#xD;
          -  Moderately severe or severe hemophilia A or B (factor VIII or factor IX &lt;= 2% by chart&#xD;
             documentation)&#xD;
&#xD;
          -  Ambulatory (ie, not wheel chair dependent)&#xD;
&#xD;
          -  Performance status - ECOG of 0 or 1 (= out of bed at least 75% of time)&#xD;
&#xD;
          -  Willing and able to comply with the requirements of the protocol and is able to give&#xD;
             informed consent&#xD;
&#xD;
        Additional inclusion criteria for MRI Substudy:&#xD;
&#xD;
          -  Baseline knee joint space width is &gt;= 3mm at the medial or lateral aspect of either&#xD;
             knee as measured by weightbearing fixed flexion PA X-ray&#xD;
&#xD;
          -  Able to undergo 1.5 or 3T MRI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to position properly for DXA&#xD;
&#xD;
          -  Presence of orthopedic hardware or other artifact in the lumbar spine (L1-L4) or&#xD;
             either proximal femur&#xD;
&#xD;
          -  Prior documentation of being HIV positive&#xD;
&#xD;
          -  Radiosynovectomy or surgical synovectomy within the last 6 months&#xD;
&#xD;
          -  Current or past treatment with bone active drugs&#xD;
&#xD;
          -  Long-term corticosteroid use [defined as 7.5-mg prednisone daily (or equivalent) for&#xD;
             &gt;= 3 months]&#xD;
&#xD;
          -  If subject is family member or employee of the investigator&#xD;
&#xD;
        Additional exclusion criteria for MRI Substudy:&#xD;
&#xD;
          -  Any contraindication or relative contraindication to MRI&#xD;
&#xD;
          -  Less than 3mm knee joint space width at the medial and lateral aspect of both knees on&#xD;
             baseline X-ray evaluation&#xD;
&#xD;
          -  Knee bleed within 30 days of informed consent&#xD;
&#xD;
          -  Prior total knee arthroplasty (TKA)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles Orthopedic Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 20, 2011</study_first_submitted>
  <study_first_submitted_qc>October 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2011</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

